Behavioural and psychological symptoms of dementia (BPSD) include affective symptoms, psychotic symptoms, non-aggressive agitation, irritability, wandering, elation and sleep problems. They have a high prevalence in dementia and nearly all people with dementia have at least one of these symptoms during the course of the disease. Such symptoms have negative effects on the quality of life of both patients and caregivers and are associated with increased costs of care. Better treatment and management of the symptoms are important, particularly as there is no effective treatment to alter the course of the underlying cognitive and functional decline. In order to design and conduct clinical trials for the treatment of BPSD, more information about the pattern of these symptoms in the different stages of dementia is needed to determine the best stage to intervene. In addition, insights into the extent to which BPSD occur over the course of dementia will help patients and care providers to plan for the future. Cross-sectional studies have shown that BPSD can occur at any time during the development of dementia. Their prevalence may increase from mild to severe dementia, whereas other studies suggest a non-linear course with the highest prevalence seen in the intermediate stages of disease. Despite heterogeneity across studies in terms of setting, focus and length of follow-up, there were clinically relevant differences in the longitudinal courses of different BPSD. Apathy was the only symptom with high baseline prevalence, persistence and incidence during the course of dementia.

Method

A systematic literature review analysed the baseline prevalence, persistence and incidence of 11 symptoms. The review was conducted according to established guidelines with the exception that we could not exclude the possibilities of bias in the studies examined.

Results

The 59 included studies showed considerable heterogeneity in their objectives and methods. The symptoms hyperactivity and apathy showed high persistence and incidence; depression and anxiety low or moderate persistence and moderate incidence; and psychotic symptoms low persistence with moderate or low incidence.

Conclusions

Despite heterogeneity across studies in terms of setting, focus and length of follow-up, there were clinically relevant differences in the longitudinal courses of different BPSD. Apathy was the only symptom with high baseline prevalence, persistence and incidence during the course of dementia.

Declaration of interest

None.

Copyright and usage

© The Royal College of Psychiatrists 2016. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) licence.

Method

Electronic searches of PubMed, EMBASE, Cinahl and PsycINFO databases were undertaken to identify potentially relevant articles published before March 2013. Search terms included text and MeSH terms for BPSD, dementia and longitudinal study (see online Fig. DS1). Two authors (R.v.d.L. and B.S.) independently searched titles and abstracts for potentially relevant articles. Following this, full text selection was completed by two authors: R.v.d.L. and A.M.P. (or B.S.). References of included studies were reviewed to ensure that there were no significant differences in the longitudinal courses of different BPSD. Apathy was the only symptom with high baseline prevalence, persistence and incidence during the course of dementia.

Behavioural and psychological symptoms of dementia (BPSD) include affective symptoms, psychotic symptoms, non-aggressive agitation, irritability, wandering, elation and sleep problems. They have a high prevalence in dementia and nearly all people with dementia have at least one of these symptoms during the course of the disease. Such symptoms have negative effects on the quality of life of both patients and caregivers and are associated with increased costs of care. Better treatment and management of the symptoms are important, particularly as there is no effective treatment to alter the course of the underlying cognitive and functional decline. In order to design and conduct clinical trials for the treatment of BPSD, more information about the pattern of these symptoms in the different stages of dementia is needed to determine the best stage to intervene. In addition, insights into the extent to which BPSD occur over the course of dementia will help patients and care providers to plan for the future. Cross-sectional studies have shown that BPSD can occur at any time during the development of dementia. Their prevalence may increase from mild to severe dementia, whereas other studies suggest a non-linear course with the highest prevalence seen in the intermediate stages of disease. Despite heterogeneity across studies in terms of setting, focus and length of follow-up, there were clinically relevant differences in the longitudinal courses of different BPSD. Apathy was the only symptom with high baseline prevalence, persistence and incidence during the course of dementia.

Method

A systematic literature review analysed the baseline prevalence, persistence and incidence of 11 symptoms. The review was conducted according to established guidelines with the exception that we could not exclude the possibilities of bias in the studies examined.

Results

The 59 included studies showed considerable heterogeneity in their objectives and methods. The symptoms hyperactivity and apathy showed high persistence and incidence; depression and anxiety low or moderate persistence and moderate incidence; and psychotic symptoms low persistence with moderate or low incidence.

Conclusions

Despite heterogeneity across studies in terms of setting, focus and length of follow-up, there were clinically relevant differences in the longitudinal courses of different BPSD. Apathy was the only symptom with high baseline prevalence, persistence and incidence during the course of dementia.

Declaration of interest

None.
searched backwards and forwards, using the literature database Scopus.

Data synthesis
Data were extracted independently and in duplicate (R.v.d.L. and B.S. or E.E.). Details extracted from each paper included setting, participant recruitment method, number of participants, follow-up time, BPSD and their measurement, number of BPSD measurements, population age (mean and range), baseline Mini-Mental State Examination (MMSE) score,14 baseline BPSD prevalence, statistical methods used, covariates taken into account and findings on the persistence, incidence and association of BPSD with cognitive function. Risk of bias was not formally assessed in a quality assessment. Findings were divided by dementia severity and BPSD. Dementia severity was defined using MMSE categories based on clinical practice guidelines from the National Institute for Health and Care Excellence (NICE): mild dementia (MMSE score 21–26), moderate dementia (MMSE 15–20), moderately severe dementia (MMSE 10–14) and severe dementia (MMSE ≤9).15 When no MMSE score was reported, equivalent cut-off scores from the Cambridge Cognitive Examination (CAMCOG), modified MMSE, Clinical Dementia Rating (CDR) scale and the Alzheimer’s Disease Assessment Scale (ADAS) were used.16–22 By use of results from factor analyses and cluster analysis reported in the literature,10 symptoms were grouped into affective symptoms (comprising depression, anxiety and apathy), psychosis (comprising delusions and hallucinations), hyperactivity (comprising irritability, agitation and wandering), elation and sleep problems.

Where possible the persistence of symptoms was reported as the percentage of people with a certain symptom at baseline who also had the symptom at the next measurement or for whom the symptom persisted during the entire follow-up period. Incidence was reported as the percentage of people without symptoms at baseline who had developed new symptoms at the next measurement or during the entire follow-up period. Results from a multistate model were reported when available. Studies investigating the association between BPSD and cognitive function were summarised by reporting the analysis methods (e.g. Cox proportional hazards model, latent class linear mixed model or logistic regression model), covariates taken into account, BPSD score and results, including hazard ratios, β coefficients and F or P values.

Baseline BPSD prevalence, persistence, incidence and association with cognitive impairment were compared for each of the symptoms in the studies that included several BPSD. Prevalence, persistence and incidence were summarised as ‘low’ if the majority of studies found that the results were lower than that of most of the other symptoms included, ‘high’ if the majority found that results were higher than for most of the other symptoms and ‘moderate’ if the results were intermediate or mixed. The range of the results was reported for each symptom.

Results
Owing to considerable heterogeneity in study objectives and methods, inclusion criteria were revised post hoc. The following exclusion criteria were added: a follow-up period of less than 3 months; reporting only the prevalence at different time points; symptom measurement through retrospective caregiver report (retrospective studies using medical records were included); and measuring pure major depression or clinical depression only. Studies reporting on minor depression or depressive symptoms only or depression as part of BPSD were included (as discussed in two previous publications).9,11 From 5923 identified articles 48 were selected for inclusion after the abstract and full-text selection stages. Cross-referencing resulted in an additional 11 studies. In total 59 studies were included.

Study design
Characteristics of the studies included are shown in Table 1 and online Table DS1. The majority of studies recruited participants from psychiatric services including memory and dementia clinics (31 studies out of 59). Participants in these studies typically had moderate dementia (16 studies) and a younger mean age (in 20 studies participants had a mean age below 75 years). Other studies recruited participants from the population (8 studies), primary care (7 studies) or institutional care (8 studies), or recruited volunteers from other settings (4 studies). One study retrospectively reviewed medical records. The 8 studies that reported on care-home residents mostly included older participants (mean age 75 years or over) with moderately severe or severe dementia. Studies recruiting participants without dementia (10 studies) were found for depression only and most of these recruited from the general population (6 studies). Overall, most studies were from the USA or Canada (27 studies) and Europe (29 studies). Follow-up times ranged from 3 months to 14 years: 8 studies had a follow-up period of 1 year or less, 24 studies a follow-up period of 1–5 years and 26 had a follow-up period of 5 years or more.

Symptoms
Included symptoms are shown in Table 1 and their baseline prevalence is summarised in Fig. 1. Full details of each symptom, its definition, the instrument used for its measurement and the baseline prevalence can be found in online Table DS2. Affective symptoms were the most frequently studied (37 studies), with 24 studies reporting on depression only. Anxiety was studied in 11 studies, apathy in 4, and 2 studies reported on a factor of affective symptoms. Psychotic symptoms were studied in 26 studies (delusions in 20, hallucinations in 21, misidentifications in 1, psychosis symptoms combined in 5). Hyperactivity symptoms, including irritability (16 studies), non-aggressive agitation (often including pacing or wandering) (16 studies), wandering (4 studies) or a factor of hyperactivity symptoms (6 studies), were studied in 30 studies. Elation was measured in only 5 studies and sleep problems in 9. Many different instruments exist to measure and define BPSD,12 and 28 different instruments were used across the included studies. The Neuropsychiatric Inventory (NPI) was used in 8 studies.23 Five studies used the total score of a BPSD instrument, rather than presenting individual symptom profiles.

Prevalence
The baseline prevalence varied widely across the studies (see Fig. 1). Generally, higher baseline prevalence was reported by studies that included a population with moderate or moderately severe dementia than by studies that included those with severe dementia only. A higher prevalence of symptoms was also seen in studies that recruited participants from psychiatric settings rather than from the population or institutional care settings (e.g. for depression: psychiatric settings 20–57%, institutional care 8–20%, population 22%). Studies with a younger mean age typically showed a higher symptom prevalence (e.g. for delusion: ≤75 years 24–40%, 75+ years 9–22%). There may also be differences by BPSD instrument. For example, studies that measured symptoms using the BEHAVE-AD typically showed a higher prevalence than studies using the NPI.
Symptom persistence and remission

The persistence and stability of symptoms or the change in symptom scores over time were considered for each of the five symptom domains separately. Figure 2 summarises the results of studies investigating the persistence of depression, hallucination and irritability (see online Fig. DS2 for the persistence of all symptoms). Detailed findings are available in online Table DS3.

Depression, anxiety and apathy

A large variation in persistence of affective symptoms was seen, with great intra-individual variability. Aalten et al reported a relatively low persistence of depression, anxiety and apathy, whereas Haupt et al reported a persistence of depression of up to 59% over a 2-year period. Anxiety and apathy may be more persistent over time than depressive symptoms, although two studies reported that anxiety was less persistent than depression. Wetzels et al (study not included in the figures because it described only the persistence over each observation) found that resolution of anxiety was consistently higher than persistence of symptoms, whereas apathy showed a variable course. Where change was modelled statistically, affective symptoms were generally found to be stable without significant change over time.

Delusions, hallucinations and misidentifications

The persistence of psychotic symptoms was mostly below 30% (5 studies), although one study reported that the 6-month persistence of delusions was 59% and hallucinations 52%. Further, multistate models by Eustace et al showed delusions were persistent over 12 months in 65%. Generally, hallucinations were less persistent than symptoms of delusion, and two studies found hallucinations were more persistent than delusions.
Irritability, agitation and wandering

Hyperactivity symptoms were mostly persistent, with one study showing that up to 76% of individuals had persistent symptoms of agitation over 2 years. Studies that investigated several hyperactivity symptoms found that agitation was more persistent than irritability. A study investigating several symptoms of irritability found that verbal aggression was the most common and longest-lasting form of aggressive behaviour, whereas aggressive resistance and physical aggression were most likely to persist until death. King-Kallimanis et al found that wandering status was more likely to change from wandering to non-wandering rather than the reverse and that wandering was a temporary phase for approximately half of care-home residents who were admitted as wanderers. Several authors analysed the course of hyperactivity over time using repeated measures analysis or a latent class linear mixed model. Garce-Olmo et al reported that over a 2-year period hyperactivity symptoms were mostly low and smoothly increasing (this pattern was found in two-thirds of participants). Cohen-Mansfield et al found that aggressive behaviours increased over time whereas physically non-aggressive behaviours did not change significantly.

Elation

The persistence of elation was investigated in only two studies. Wetzels et al found in severe dementia that, for each two consecutive assessments at 0–6 months, 6–12 months, 12–18 months and 18–24 months, symptoms were stable in 39%, 18%, 3% and 3% respectively. Over a total follow-up period of 2 years Aalten et al found in moderate dementia that symptoms were stable over a 6-month period in 2%, whereas for none of the participants did symptoms persist over 12 months, 18 months or 24 months. Therefore, these results suggest that elation is not persistent.

Sleep problems

Most studies that investigated sleep problems (4 studies) reported low persistence, or a fluctuating course. In only one study were sleep symptoms reported to be persistent.
Fig. 2  Persistence of (a) depression, (b) irritability and (c) hallucinations. Squares indicate the reported percentage where the symptom persisted over the measurement period and the lines indicate 95% confidence intervals. The name of the first author is given next to the corresponding findings. If the study reported the persistence over several intervals, it is included in the figure more than once. Next to the name of the author the total follow-up time (in months unless specified) and the number of visits are reported. For example, Aalten et al measured symptoms at 5 visits over 24 months and reported on the percentage of participants with depression present at any consecutive period of 6 months (depression present at 2 visits), 12 months (present at 3 visits), 18 months (present at 4 visits) or 24 months (present at 5 visits).
Incidence and absence of symptoms

Online Table DS4 and Fig. DS3 show the incidence of symptoms and the percentage of participants who did not have symptoms during the follow-up period. A summary is shown in Fig. 3.

Depression, anxiety and apathy

Affective symptoms commonly develop in people with dementia. Over a 1-year period a high or moderate depression incidence of up to 37% was reported by eight studies, whereas in others the onset of depression was low compared with other symptoms. The incidence of apathy has been reported to be particularly high: 64% over 2 years, and 14–27% over a 6-month period.

Delusions, hallucinations and misidentifications

In four studies the probability of new-onset hallucinations was reported to be low, whereas in another four incidence was reported to be moderate or high. Other psychotic symptoms including delusions showed a consistently moderate incidence (11 studies). Also, irritability, agitation and wandering were studied in 11 and 10 studies, respectively. Although the incidence of agitation might be particularly high, during a maximum follow-up of 4 years in 8%, the probability of the onset of sleep problems was reported to be low, whereas in another study was reported to be moderate or high.

Irritability, agitation and wandering

All included studies that compared the incidence of hyperactivity with other symptoms (9 studies) concluded that the incidence of hyperactivity was high or moderate. Although the incidence of agitation might be particularly high, wandering might develop less often.

Elation

The incidence of elation was investigated by three studies that used the NPI. Aalten et al reported a cumulative incidence over a 2-year period in 5%, whereas in another study was reported to be low, and Gillette-Guyonnet et al reported that new symptoms developed during a maximum follow-up of 4 years in 8%. These results suggest the incidence of elation is low.

Sleep problems

The probability of the onset of sleep problems was reported in four studies. No consistent findings were reported: at each 6-month period the incidence in one study was 15%, and in another 2–8%, whereas over a total follow-up of 2 years symptoms developed in 31% and over 4 years in 11%.

Association with cognitive function

The results of studies investigating the association between the course of BPSD and cognitive function (25 studies) are summarised in online Table DS5.

BPSD and subsequent cognitive function

Eight studies investigated the association between depression and subsequent cognitive decline or development of dementia in those without dementia at baseline. Those with persistent depression showed significant decline over time in global cognitive function, memory, processing speed, recall and attention. Some found a slight increase in depression score before dementia diagnosis compared with those who did not develop dementia, whereas others did not find a significant change in depression before dementia diagnosis. In those with dementia, associations with progression of cognitive function were found for psychosis, hyperactivity, and depression. Two studies investigated the link between BPSD and mild cognitive impairment. In one study persistence of depression was associated with progression to dementia, whereas another reported no difference in persistence between those who were cognitively stable and those who progressed to dementia.

Cognitive function and BPSD development

In individuals with dementia, psychosis, hyperactivity, agitation and physical aggression were associated with greater cognitive impairment. In contrast, Marin et al found no association in dementia between cognitive impairment and depression, delusion, agitation and irritability. Four studies found that symptoms increased with cognitive decline in the early stages of dementia and were most commonly seen in moderate dementia, followed by a declining or stable course in the final stages of dementia. Cognitive function at onset of wandering was found to differ by type of wandering behaviour; for example, results suggested that excessive walking was more common in mild dementia, whereas in severe dementia getting lost was more likely. No association was found between cognitive function and depressive symptoms in those with dementia, whereas in those without dementia and without depression at baseline, cognitive impairment at baseline was associated with an increase of depressive symptoms over time. In those aged 70 years and over cognitive function was found to be associated with initial scores for depression and anxiety, but not with symptom change over time. Baseline dementia diagnosis was not significantly associated with severity of depression at follow-up.

Comparison of symptoms

We summarised the studies investigating several BPSD to compare baseline prevalence, stability, incidence and association with cognitive function for each of the symptoms (Table 2). Some symptoms were studied more often than others, and evidence is lacking for infrequently studied symptoms such as wandering (included in only one study investigating several BPSD), and apathy and elation (included in only four studies). Depressive symptoms were most often studied (included in 12 of the 13 studies investigating several BPSD). Compared with other symptoms, the results suggest that the persistence and incidence of depressive symptoms are moderate. Anxiety seems to be less prevalent and was reported to have a moderate persistence and incidence. The few studies investigating apathy suggest a high prevalence, persistence and incidence of symptoms. The prevalence, persistence and incidence of psychotic symptoms were suggested to be low to moderate, and may be particularly low for hallucinations. Symptoms of hyperactivity were most frequently seen and the majority of studies reported a higher persistence and incidence compared with other symptoms.

Discussion

This systematic review confirms that BPSD are common and relatively persistent in individuals with dementia. The results suggest there are differences between symptoms: hyperactivity and apathy showed high persistence and incidence; depression and anxiety low or moderate persistence and moderate incidence; and psychotic symptoms low persistence and a moderate or low incidence. Studies of the association between BPSD and cognitive function suggest that in those without dementia the presence of depression is associated with subsequent cognitive decline. In
Fig. 3 Incidence of (a) depression, (b) irritability and (c) hallucinations. See Fig. 2 for an explanation of the symbols. NR, not reported.
those with dementia, psychosis, hyperactivity, agitation and physical aggression were associated with greater cognitive impairment.

**Strengths and limitations**

Standardised procedures were used for the literature search and data extraction, including double reading to ensure quality. However, no established search term for BPSD exists and therefore relevant studies may have been missed. The reference lists of included articles and reviews were searched to minimise the number of missed articles. The review included studies with a high degree of heterogeneity in study design and population characteristics, including large differences in the period over which the persistence and incidence was reported (1 month to 4 years), the total follow-up time (3 months to 14 years), the instrument and cut-off score used to measure symptoms, the number of symptoms measured, dementia severity, recruitment setting and mean age. This made cross-study comparisons difficult and a meta-analysis was not possible. We were not able to investigate whether the course of BPSD differs between types of dementia as only five of the 59 studies reported findings by dementia type. We adhered to most of the items of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (see online Table DS6).

The prevalence of symptoms varied across the studies and between symptoms. Depression, apathy, irritability, agitation and wandering showed a high prevalence, whereas the prevalence of anxiety, hallucination and elation was low. Some studies consistently reported a relatively low prevalence of symptoms, whereas others consistently reported a relatively high prevalence. Differences might be due to variability in study design, population characteristics or measurement of symptoms. Indeed, a higher prevalence of symptoms was generally seen in studies that included a sensitivity analysis the results were not altered when taking into account medication use. As we are not aware of a formal definition of high prevalence, persistence or incidence, we summarised the findings as 'low' if the majority of studies found that the results were lower than that of most of the other symptoms included, 'high' if the majority found that results were higher than for most of the other symptoms and 'moderate' if the results were intermediate or mixed.

**Interpretation of findings**

**Prevalence**

The prevalence of symptoms varied across the studies and between symptoms. Depression, apathy, irritability, agitation and wandering showed a high prevalence, whereas the prevalence of anxiety, hallucination and elation was low. Some studies consistently reported a relatively low prevalence of symptoms, whereas others consistently reported a relatively high prevalence. Differences might be due to variability in study design, population characteristics or measurement of symptoms. Indeed, a higher prevalence of symptoms was generally seen in studies that recruited participants with less severe dementia, in studies that recruited from psychiatric settings rather than from the population or institutional care settings, and in studies with a younger mean age. There may also be differences due to the BPSD instrument used.

---

**Table 2 Results of 13 studies reporting at least two behavioural and psychotic symptoms of dementia**

| Symptoms         | Number of studies | Baseline prevalence (%) | Persistence (%) | Incidence (%) |
|------------------|-------------------|-------------------------|-----------------|--------------|
|                  | Number of studies | Baseline prevalence (%) | Persistence (%) | Incidence (%) |
|                  | 11 studies        |                         | 10 studies      | 9 studies    |
| Affective        | 12                | High                    | Moderate        | Moderate     |
| Depression       | 12                | High (8-57%)            | Moderate (16-70) | Moderate (10-73) |
| Anxiety          | 8                 | High (17-52%)           | Moderate (17-52) | Moderate (12-38) |
| Apathy           | 4                 | High (19-51)            | High (20-55)    | High (27-64)  |
| Psychosis        | 13                | Low                     | Moderate        | Moderate     |
| Delusions        | 10                | Moderate (9-40)         | Low (0-82)      | Low (0-52)    |
| Hallucinations   | 11                | Low (0-18)              | Low (0-52)      | Low (0-43)    |
| Hyperactivity    | 12                | High                    | High            | High         |
| Irritability     | 9                 | High (6-57)             | Moderate (12-80) | High (10-69)  |
| Agitation        | 7                 | High (18-87)            | Moderate (21-77) | High (19-80)  |
| Wandering        | 1                 | NR                      | High (60)       | NR           |
| Elation          | 4                 | Low (3-9)               | Low (2-39)      | Low (4-5)     |
| Sleep problems   | 7                 | Moderate (6-11)         | Low (10-57)     | Low (8-31)    |

NR, not reported.

a. Percentage of symptoms persistent over 3 months or more.
b. Percentage incidence over 3 months or more.

---

and symptoms were mostly shown to be persistent, stable or increasing. The incidence reported by the studies using the NPI was low or moderate compared with studies using other instruments.

Loss to follow-up is a challenge in longitudinal studies, and we have reported the number of participants at the end of the follow-up period for the included studies (online Table DS1). There was large variation in follow-up completion (24–100%), although often not reported and reasons for leaving the study were often not reported. Persistence of BPSD may be associated with mortality and with refusal to participate in follow-up interviews, and differences in follow-up completion may have influenced the results. Furthermore, we have used study baseline as a proxy for disease and symptom onset and this may have affected the findings on the persistence of symptoms. Symptom course may be influenced by pharmacological or non-pharmacological interventions. Although there was large variation in medication use between study populations, in the majority of studies that included a sensitivity analysis the results were not altered when taking into account medication use. As we are not aware of a formal definition of high prevalence, persistence or incidence, we summarised the findings as ‘low’ if the majority of studies found that the results were lower than that of most of the other symptoms included, ‘high’ if the majority found that results were higher than for most of the other symptoms and ‘moderate’ if the results were intermediate or mixed.

**Strengths and limitations**

Standardised procedures were used for the literature search and data extraction, including double reading to ensure quality. However, no established search term for BPSD exists and therefore relevant studies may have been missed. The reference lists of included articles and reviews were searched to minimise the number of missed articles. The review included studies with a high degree of heterogeneity in study design and population characteristics, including large differences in the period over which the persistence and incidence was reported (1 month to 4 years), the total follow-up time (3 months to 14 years), the instrument and cut-off score used to measure symptoms, the number of symptoms measured, dementia severity, recruitment setting and mean age. This made cross-study comparisons difficult and a meta-analysis was not possible. We were not able to investigate whether the course of BPSD differs between types of dementia as only five of the 59 studies reported findings by dementia type. We adhered to most of the items of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (see online Table DS6).

Although we have reported on a range of factors that might influence the quality of the study, risk of bias was not formally assessed in a quality assessment. Our review therefore does not meet items 12, 15, 19 and 22 of the guidelines. Bias in the included studies may have led to an overestimate of persistence (e.g. participants remained under medical attention) or to an underestimate of persistence (e.g. gaps in the follow-up period or attrition through death or care-home admission). In addition, the review protocol was not registered.

**Study differences**

Many different instruments exist to measure BPSD, and 28 different instruments were used by the studies included in this review. However, the increasing use of the NPI might improve comparability of future studies. The NPI was used by eight studies. In these studies the baseline prevalence seemed lower than that reported by studies using other instruments (e.g. for irritability, NPI rates were 19–37%; Present Behavioural Examination (PBE) 25–89% and BEHAVE-AD 42–57%). The total score on the NPI significantly increased over time, and symptoms were mostly shown to be persistent, stable or increasing. The incidence reported by the studies using the NPI was low or moderate compared with studies using other instruments.

Loss to follow-up is a challenge in longitudinal studies, and we have reported the number of participants at the end of the follow-up period for the included studies (online Table DS1). There was large variation in follow-up completion (24–100%), although often not reported and reasons for leaving the study were often not reported. Persistence of BPSD may be associated with mortality and with refusal to participate in follow-up interviews, and differences in follow-up completion may have influenced the results. Furthermore, we have used study baseline as a proxy for disease and symptom onset and this may have affected the findings on the persistence of symptoms. Symptom course may be influenced by pharmacological or non-pharmacological interventions. Although there was large variation in medication use between study populations, in the majority of studies that included a sensitivity analysis the results were not altered when taking into account medication use. As we are not aware of a formal definition of high prevalence, persistence or incidence, we summarised the findings as ‘low’ if the majority of studies found that the results were lower than that of most of the other symptoms included, ‘high’ if the majority found that results were higher than for most of the other symptoms and ‘moderate’ if the results were intermediate or mixed.

**Interpretation of findings**

**Prevalence**

The prevalence of symptoms varied across the studies and between symptoms. Depression, apathy, irritability, agitation and wandering showed a high prevalence, whereas the prevalence of anxiety, hallucination and elation was low. Some studies consistently reported a relatively low prevalence of symptoms, whereas others consistently reported a relatively high prevalence. Differences might be due to variability in study design, population characteristics or measurement of symptoms. Indeed, a higher prevalence of symptoms was generally seen in studies that recruited participants with less severe dementia, in studies that recruited from psychiatric settings rather than from the population or institutional care settings, and in studies with a younger mean age. There may also be differences due to the BPSD instrument used.
Persistence

Large differences in persistence were seen across symptom groups and individual symptoms. Affective symptoms (including depression, anxiety and apathy) generally showed a moderate persistence, although a limited number of studies reported persistence of apathy to be high and in one study it was reported to be higher than for any other symptom. Persistence of psychosis was low to moderate. In contrast, hyperactivity symptoms showed a high persistence. This is an issue of concern as these symptoms are among those most problematic for caregivers. A low persistence was seen for elation and sleep problems. Differences in symptom persistence may reflect the nature of the symptom or might be explained by factors such as more widely available treatment options for depression and anxiety. Differences in dementia severity and baseline BPSD prevalence are likely to have affected results on persistence of symptoms. Persistence may be higher in those with more severe cognitive impairment at baseline, and a higher BPSD prevalence. However, associations between study characteristics and results could not be tested because of the large degree of heterogeneity in study design and population characteristics.

Incidence

The results suggest that affective symptoms and hyperactivity symptoms commonly develop in people with dementia. Large differences in reported incidence were seen between studies. For example, the reported incidence of depression ranged from 12% over a mean follow-up period of 32 months, to 73% over a maximum follow-up period of 9.3 years. Differences in study design and differences in baseline prevalence of symptoms are likely to have influenced the results. For example, the reported incidence might be higher in studies that reported a high baseline prevalence, compared with studies with a low baseline prevalence, although no formal analysis of the association between study characteristics and incidence was possible.

Role of cognition

The presence of depression before the onset of dementia was associated with subsequent cognitive decline. In dementia, psychosis, hyperactivity, agitation and physical aggression were associated with greater cognitive impairment. Symptoms may be most common in moderate dementia, followed by a declining or stable course in the final stages of dementia. However, heterogeneity in the pattern of findings across studies investigating the associations between BPSD and cognitive function prevented us from drawing more specific conclusions. The heterogeneity of results does, however, suggest that BPSD do not solely arise secondary to cognitive impairment.

Study implications

The results from this systematic review suggest that some symptoms such as hyperactivity are more persistent than others such as elation and sleep problems. In particular apathy, irritability, agitation and wandering showed a high persistence. These symptoms should be targeted in clinical trials to improve management and intervention. Clinical trials typically follow participants with more severe dementia over a short period. However, results presented here show that symptoms may persist over long periods until death, and may be most common in moderate dementia. Clinical trials focusing on the earlier stages of dementia with a long follow-up time might therefore be particularly informative. Results could also inform patients and care providers about which symptoms are most likely to recur, so that measures can be put in place to reduce their impact. Recommendations for monitoring of patients and symptom management interventions are outlined in guidance by the Alzheimer’s Society.

Future research

The heterogeneity in methods and results emphasises the importance of clearly reporting the study design, population characteristics and symptom definitions. Table 1 shows that studies typically included younger populations with moderate dementia, whereas studies recruiting those with mild or moderate dementia from the population or from primary care settings were lacking. As BPSD patterns may differ in these populations, they should be the focus of future studies. In addition, all included studies were conducted in high-income countries and the findings may therefore not be applicable outside these settings. Apathy was infrequently studied, and as the limited results suggest that it may have a high persistence and incidence, we recommend that this symptom should be the focus of future studies on symptom course.

These methodological issues reiterate the findings from several of our previous reviews. A review of reviews showed a focus on individual symptoms (particularly depression), raised the question how best to define and measure BPSD within and across populations, and recommended reporting more clearly the characteristics of the population, the inclusion and exclusion criteria and how BPSD were defined and measured. Two reviews concluded that there were many instruments to measure BPSD, of which the NPI – a short, informant-based questionnaire measuring ten symptoms – has been cited most frequently and should form the core of any battery, although researchers choosing instruments should carefully address any gaps in its content with regard to their research question. In a guest editorial we discussed that the populations used in studies of depression and BPSD are often not quite comparable and that the results therefore cannot be readily extrapolated. Finally, we showed that studies investigating symptom groups show relatively consistent results, although there remains a large amount of individual variability.

Studying covariates that may be associated with higher persistence of BPSD, including impairment in activities of daily living, as well as medication use, could improve understanding of potential mechanisms involved in the presence and persistence of BPSD. Environmental factors such as overstimulation and a person’s surroundings, as well as physical factors such as pain and dehydration, are recognised as important triggers for BPSD. These factors are often difficult to capture and have not been investigated in the studies included here.
is not a unitary phenomenon. These findings are relevant to clinicians as they indicate which symptoms may be expected to persist or to occur anew, and therefore give a better understanding of the natural history of BPSD which, in turn, can influence approaches to management and treatment.

**References**

1. Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. *Int Psychogeriatr* 1996; 8 (suppl 3): 497–500.

2. Savva GM, Zaccai J, Matthews FE, Davidson JE, McKeith I, Brayne C. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. *Br J Psychiatry* 2009; 194: 212–19.

3. Black W, Almeida OP. A systematic review of the association between the behavioral and psychological symptoms of dementia and burden of care. *Int Psychogeriatr* 2004; 16: 295–315.

4. Beeri MS, Wener P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer’s disease patients. *Int J Geriatr Psychiatry* 2002; 17: 403–8.

5. Purandare N, Allen NH, Burns A. Behavioural and psychological symptoms of dementia. *Rev Clin Gerontol* 2000; 10: 245–60.

6. Lovheim H, Sandman PO, Karlsson S, Gustafson Y. Behavioural and psychological symptoms of dementia in relation to level of cognitive impairment. *Int Psychogeriatr* 2008; 20: 777–89.

7. Wetzelis R, Zuidema S, Jansen I, Verhey F, Koopmans R. Course of neuropsychiatric symptoms in residents with dementia in long-term care institutions: a systematic review. *Int Psychogeriatr* 2010; 22: 1040–53.

8. Selbach G, Engedal K, Bergh S. The prevalence and course of neuropsychiatric symptoms in nursing home patients with dementia: a systematic review. *J Am Med Dir Assoc* 2013; 14: 161–9.

9. Van der Linde RM, Stephan BC, Savva GM, Dening T, Brayne C. Systematic reviews on behavioural and psychological symptoms in the elderly or demented population. *Alzheimers Res Ther* 2012; 4: 28.

10. Van der Linde RM, Dening T, Matthews FE, Brayne C. Grouping of behavioural and psychological symptoms of dementia. *Int J Geriatr Psychiatry* 2014; 29: 562–8.

11. Van der Linde RM, Brayne C, Dening T. Depression and other behavioral and psychological symptoms of dementia – separate research worlds in need of a common understanding. *Int Psychogeriatr* 2014; 26: 177–83.

12. Van der Linde RM, Stephan BC, Dening T, Brayne C. Instruments to measure behavioural and psychological symptoms of dementia. *Int J Methods Psychiatr Res* 2014; 23: 69–98.

13. Van der Linde R, Stephan B, Dening T, Brayne C. Instruments to measure behavioural and psychological symptoms of dementia: changing use over time. *Int J Geriatr Psychiatry* 2013; 28: 433–5.

14. Folstein MF, Folstein SE, McHugh PR. ‘Mini­-mental state’. A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975, 12: 189–98.

15. National Institute for Health and Care Excellence. Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer’s Disease. NICE Technology Appraisal Guidance (TA217). NICE, 2011.

16. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, et al. CAMDEX: A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. *Br J Psychiatry* 1986; 149: 698–709.

17. Blessed G, Black SE, Butler T, Kay DW. The diagnosis of dementia in the elderly: A comparison of CAMCOG (the cognitive section of CAMDEX), the AGECAT program, DSM-III, the Mini-Mental State Examination and some short rating scales. *Br J Psychiatry* 1991; 159: 193–8.

18. Devanand DP, Jacobs DM, Tang MX, Del Castillo-Castaneda C, Sano M, Marder K, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. *Arch Gen Psychiatry* 1997; 54: 257–63.

19. Teng EL, Chui HC. The Modified Mini-Mental State (MMS) examination. *J Clin Psychiatry* 1992; 48: 314–8.

20. Hughes CP, Berg L, Danziger WL, Cohen LA, Martin RL. A new clinical scale for the staging of dementia. *Br J Psychiatry* 1982; 140: 566–72.

21. Juva K, Sulkava R, Eriknijittu Y, Yliskoski R, Valvanne J, Tijlv S. Staging the severity of dementia: comparison of clinical (CDR, DSM-III-R), functional (ADL, IADL) and cognitive (MMSE) scales. *Acta Neurol Scand* 1994; 90: 293–8.

22. Cano SJ, Posner HB, Moline ML, Hurt SW, Swartz J, Hsu T, et al. The ADAS-cog in Alzheimer’s disease clinical trials: psychometric evaluation of the sum and its parts. *J Neurol Neurosurg Psychiatry* 2010; 81: 1363–8.

23. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. *Neurology* 1994; 44: 2380–14.

24. Fauth EB, Zant SH, Femia EE, Hofer SM, Stephens MAP. Behavioral and psychological symptoms of dementia and caregivers’ stress appraisals: intra-individual stability and change over short-term observations. *Aging Ment Health* 2006; 10: 563–73.

25. Neundorfer MM, McClendon MJ, Smyth KA, Stuckey JC, Strauss ME, Patterson MB. A longitudinal study of the relationship between levels of depression among persons with Alzheimer’s disease and levels of depression among their family caregivers. *J Gerontol Ser B Psychol Sci Soc Sci* 2001; 56: 301–13.

26. Aalten P, de Vugt MG, Jaspers N, Holleg J, Verhey FR. The course of neuropsychiatric symptoms in dementia. Part 1: findings from the two-year longitudinal Maasbed study. *Int J Geriatr Psychiatry* 2005; 20: 523–30.

27. Haupt M, Kurz A, Janner M. A 2-year follow-up of behavioural and psychological symptoms in Alzheimer’s disease. *Dement Geriatr Cogn Disord* 2000; 11: 147–52.

28. Ustace A, Coen R, Walsh C, Cunningham CJ, Walsh JB, Coakley D, et al. A longitudinal evaluation of behavioural and psychological symptoms of probable Alzheimer’s disease. *Int J Geriatr Psychiatry* 2002; 17: 968–73.

29. Berger G, Bernhardt T, Weimer E, Peters J, Kratzsch T, Frolich L. Longitudinal study on the relationship between symptomatology of dementia and levels of subjective burden and depression among family caregivers in memory clinic patients. *J Geriatr Psychiatry Neurol* 2005; 18: 119–28.

30. Hope T, Keene J, Fairburn CG, Jacoby R, McShane R. Natural history of behavioural changes and psychiatric symptoms in Alzheimer’s disease. A longitudinal study. *Br J Psychiatry* 1999; 174: 39–44.

31. Wetzelis RB, Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT. Course of neuropsychiatric symptoms in residents with dementia in nursing homes over 2-year period. *Am J Geriatr Psychiatry* 2010; 18: 1054–65.

32. Garre-Olmo J, Lopez-Pousa S, Villalta-Franch J, De Gracia Blanco M, Villarasa AB. Grouping and trajectories of neuropsychiatric symptoms in patients with Alzheimer’s disease. Part II: Two-year patient trajectories. *J Alzheimers Dis* 2010; 22: 1169–80.

33. Zahodne LB, Devanand DP, Stern Y. Coupled cognitive and functional change in Alzheimer’s disease and the influence of depressive symptoms. *J Alzheimers Dis* 2013; 34: 851–60.

34. Clare L, Nells SM, Martyr A, Whitteraker CJ, Markova IS, Roth I, et al. Longitudinal trajectories of awareness in early-stage dementia. *Alzheimer Dis Assoc Disord* 2012; 26: 140–7.

35. Holtzer R, Tang MX, Devanand DP, Albert SM, Wegesin DJ, Marder K, et al. Psychopathological features in Alzheimer’s disease: course and relationship with cognitive status. *J Am Geriatr Soc* 2003; 51: 953–60.

36. Keene J, Hope T, Fairburn CG, Jacoby R, Gedling K, Ware CJ. Natural history of aggressive behaviour in dementia. *Int J Geriatr Psychiatry* 1999; 14: 541–8.
veterans affairs nursing home care units. Int J Geriatr Psychiatry 2010; 25: 164–74.

38 Cohen-Mansfield J, Werner P. Longitudinal changes in behavioral problems in old age: a study in an adult day care population. J Gerontol A Biol Sci Med Sci 1996; 53: M65–71.

39 Levy ML, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta A. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer’s disease. Am J Psychiatry 1996; 153: 1438–43.

40 Scarmeas N, Brandt J, Albert M, Devanand DP, Marder K, Bell K, et al. Association between the APOE genotype and psychopathologic symptoms in Alzheimer’s disease. Neurology 2002; 58: 1162–8.

41 Ballard CG, Patel A, Solis M, Lowe K, Wilcock G. A one-year follow-up study of depressives in dementia sufferers. Br J Psychiatry 1996; 168: 287–91.

42 Li YS, Meyer JS, Thobny J. Longitudinal follow-up of depressive symptoms among normal versus cognitively impaired elderly. Int J Geriatr Psychiatry 2001; 16: 718–77.

43 Scarmeas N, Brandt J, Blacker D, Albert M, Hadjigeorgiou G, Dubois B, et al. Disruptive behavior as a predictor in Alzheimer disease. Arch Neurol 2007; 64: 1755–61.

44 Chang JB, Wang PN, Chen WT, Liu CY, Hong CJ, Lin KN, et al. APOE-ε4 allele is associated with incident hallucinations and delusions in patients with AD. Neurology 2004; 63: 1105–7.

45 Rosen J, Zubenko GS. Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer’s disease. Biol Psychiatry 1991; 29: 222–34.

46 Wilkosz PA, Miyahara S, Lopez OL, DeCosky ST, Sweet RA. Prediction of psychosis onset in Alzheimer disease: the role of cognitive impairment, depressive symptoms, and further evidence for psychosis subtypes. Am J Geriatr Psychiatry 2006; 14: 352–60.

47 Ballard C, O’Brien J, Coope B, Fairbairn A, Abid F, Wilcock G. A prospective study of psychotic symptoms in dementia sufferers: psychosis in Alzheimer’s. Int Psychogeriatr 1997; 9: 57–64.

48 Chen JY, Stern Y, Sano M, Mayeux R. Cumulative risks of developing extrapyramidal signs, psychosis, or myoclonus in the course of Alzheimer’s disease. Arch Neurol 1991; 48: 1141–3.

49 Caligiuri MP, Peavy G, Salmon DP, Galasko DR, Thal LJ. Neuromotor abnormalities and risk for psychosis in Alzheimer’s disease. Neurology 2003; 61: 954–8.

50 Mc Shane R, Keene J, Fairburn C, Jacoby R, Hope T. Psychiatric symptoms in patients with dementia predict the later development of behavioural abnormalities. Psychol Med 1998; 28: 1119–27.

51 Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Gardevette V, Coley N, Cantet C, et al. Long-term progression of Alzheimer’s disease in patients under antidementia drugs. Alzheimers Dement 2011; 7: 579–92.

52 Kohler S, van Boxtel MP, van Os J, Thomas AJ, O’Brien JT, Jolles J, et al. Depressive symptoms and cognitive decline in community-dwelling older adults. J Am Geriatr Soc 2010; 58: 873–9.

53 Dotton VM, Resnick SM, Zonderman AB. Differential association of concurrent, baseline, and average depressive symptoms with cognitive decline in older adults. Am J Geriatr Psychiatry 2008; 16: 318–30.

54 Vinkers DJ, Gusselko J, Stek ML, Westendorp RGJ, Van Der Mast RC. Temporal relation between depression and cognitive impairment in old age: prospective population based study. BMJ 2004; 329: 881–3.

55 Aminiha E, Le Goff M, Millet X, Oreggozo JM, Peres K, Barberger-Gateau P, et al. Prodromal Alzheimer’s disease: successive emergence of the clinical symptoms. Ann Neurol 2008; 64: 492–8.

56 Wilson RS, Arnold SE, Beck TL, Bienen AL, Bennett DA. Change in depressive symptoms during the prodromal phase of Alzheimer disease. Arch Gen Psychiatry 2008; 65: 439–46.

57 Becker JT, Chang YF, Lopez OL, Dew MA, Sweet RA, Barnes D, et al. Depression margin not a risk factor for incident dementia in a community-based cohort. Am J Geriatr Psychiatry 2009; 17: 653–60.

58 Bleik AA, Gerstorf D, Kiely KM, Anstey KJ, Luszcz M. Depressive symptoms predict decline in perceptual speed in older adulthood. Psychol Aging 2011; 26: 576–83.

59 Wilson RS, Hoganson GM, Rajan KB, Barnes LL, Mendes de Leon CF, Evans DA. Temporal course of depressive symptoms during the development of Alzheimer disease. Neurology 2010; 75: 214–6.

60 Haupt M, Romero B, Kurz A. Delusions and hallucinations in Alzheimer’s disease: results from a two-year longitudinal study. Int J Geriatr Psychiatry 1996; 11: 965–72.

61 Houdé M, Bergman H, Whitehead V, Chertkow H. A predictive depression pattern in mild cognitive impairment. Int J Geriatr Psychiatry 2008; 23: 1028–33.
Inside Out: education or simply entertainment?
Hannah Marcarian and Paul O. Wilkinson

Inside Out is a 2015 Pixar computer-animated film set inside the brain of a 11-year-old girl Riley. The film tries to provide an insight into the workings of a child’s mind and so has the potential to be educational for children in their understanding of emotional balance. Riley’s emotions – Joy, Anger, Disgust, Fear and Sadness – are characters that control her actions via the Control Centre of her brain, with Joy their leader. When we meet the first four emotions, they tell us their clear role in Riley’s life. However, Sadness seems to have no purpose and Joy tries to sideline her as much as possible.

Riley is a happy child until a significant life event occurs: moving from Minnesota to San Francisco. We see difficult changes happen in Riley’s real life: moving away from her friends and hockey team, moving to a smaller house, her parents being stressed and finding it hard to make friends at her new school. Her mum asks her to keep up a happy face, to help them all to cope better. Riley (and Joy) try to do this. Unsurprisingly, this attempt to be happy when life is problematic is a real struggle. We see the battle in the Control Centre, predominantly between Joy and Sadness. Sadness tries to make a ‘core memory’ of a difficult event at school. This is horrifying to Joy, who thinks all core memories should be positive. This battle leads to Joy and Sadness both being sucked out of the Control Centre.

The film then portrays what life is like without Joy and Sadness. Other emotions control Riley, principally Anger, reflecting how young people’s sadness often presents as anger (in fact, DSM allows irritability to be a core symptom of paediatric depression, instead of sadness). Life continues to go badly and Riley’s parents struggle to understand her; they see her as a moody teenager who needs to be disciplined, which sometimes happens with parents adolescents with depression. Relationships deteriorate and Anger makes Riley plan to run away from home, rather than attempting more constructive actions.

Joy and Sadness try to make their way back to the Control Centre. Initially, Joy is exasperated with Sadness who wants ‘to obsess over the weight of life’s problems’, and tries to leave her behind. This is despite Sadness making some sensible suggestions, like not following Bing Bong. Riley’s rather foolish imaginary friend, into a dangerous place when warning signs say keep out – of course, optimistic Joy decides they should go in anyway. Over time, Joy finds that she cannot return without Sadness and begins to realise Sadness is helpful, after watching her comfort Bing Bong. Sadness allows him to feel sad and listens, which makes him feel better. Joy recalls a happy core memory that actually had an aspect of sadness: Riley’s team had lost, but when her parents saw her feeling sad, they knew they needed to comfort her, helping her to feel happy. Joy and Sadness eventually return to the Control Centre where Joy sees that Riley is running away to Minnesota and invites Sadness to take control. Riley feels sad and this motivates her to return to her worried parents. They hug their daughter, who cries while explaining her feelings. They acknowledge that the move has been hard for Riley, validating her.

While not about mental illness, the film helps educate children about how to deal with feelings. Sadness is real, we can’t get rid of it and trying to suppress it leads to other problems. Allowing sadness to be expressed can let other people help us. Hopefully, it also teaches parents to listen to their children at times of big family changes, especially if they seem angry.